BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The results showed that the combination index values of imatinib and b‐AP15 at most doses were lower than 1 in BCR‐ABLWT and BCR‐ABLT315I CML cells, indicating a synergism between imatinib and b‐AP15 (Figure 7A).